SCHEMBL13035401

SCHEMBL13035401

NCc1cnn(C2CCCCO2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRR1 P24046 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
ALDH1A1 P00352 2/20 0.38
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
KDM5B Q9UGL1 1/20 0.38
OGA O60502 1/20 0.37
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
CYP4F2 P78329 4/20 0.33
CYP4A11 Q02928 4/20 0.33
FLT3 P36888 2/20 0.33
FGFR1 P11362 2/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22774288 0.85 KDM5B (0.40) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL878011 0.85 KDM5B (0.38) ALDH1A1LMNAPOLBKDM5BOGA
SCHEMBL29525193 0.85 KDM5B (0.40) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL31510377 0.85 KDM5B (0.40) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL35212261 0.82 FLT3 (0.38) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL31180433 0.81 KDM5B (0.36) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL15760929 0.81 RXRA (0.38) ALDH1A1LMNAPOLBKDM5BOGA
SCHEMBL15286385 0.81 KDM5B (0.39) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL16353569 0.80 ALDH1A1 (0.44) ALDH1A1LMNAPOLBKDM5BRXRA
SCHEMBL17007901 0.79 KDM5B (0.37) ALDH1A1LMNAPOLBKDM5BRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4590674-A1 NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2025-07-30 EP disclosed
EP-4229049-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-08-23 EP disclosed
CN-116547278-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2023-08-04 CN disclosed
EP-4204415-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2023-07-05 EP disclosed
WO-2022078380-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 WO disclosed
WO-2022078380-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-04-21 WO disclosed
WO-2022042691-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO, INC. (US) 2022-03-03 WO disclosed
US-20100298314-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298314-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK2, MAP4K2 GABRA1 3957/4885GABRR1 3639/4885GABRA3 4347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.